• STARR2: A new approach for treating COPD exacerbations

    Point-of-care eosinophil-guided prednisolone was non-inferior to its standard-of-care prescription in treating COPD exacerbations, a trial showed.

  • The great debate: Will AI soon replace the medical profession?

    Cardiology moves between life and death. The extent to which artificial intelligence could help or replace doctors in this field is a subject of passionate debate.

  • Fruquintinib: a potential treatment option for refractory mCRC patients

    A trial demonstrated a doubling of PFS and a near doubling of overall survival with the VEGF-1, -2, and -3 inhibitor in patients with refractory mCRC.

  • Heart failure in smokers diagnostically visible

    According to a study, smokers suffer from heart failure more frequently than non-smokers of the same age. The underlying changes in the heart are visible.

  • AI-enhanced echography supports aortic stenosis patients

    Echocardiography to assess aortic stenosis severity, supported by a novel AI algorithm, can better identify patients at high death risk who could benefit from treatment.

  • Conservative or invasive management for high-risk kidney disease with ischaemia?

    An invasive ischaemia treatment in CKD and chronic coronary disease patients was not superior to conservative management for deaths reduction after 5 years.

  • ARBs + beta-blockers may delay Marfan syndrome aortic root replacement

    A meta-analysis in Marfan syndrome patients concluded that both drugs have similar, substantial, and independent effects on reducing aortic root size.

  • AXIOMATIC-SSP trial: Reducing risks of ischaemic stroke with factor XIa inhibition?

    The trial showed that dose response was not observed, yet a 30% relative risk reduction was seen in symptomatic ischaemic strokes with milvexian.

  • Rheumatic heart disease-associated AF: standard-of-care holds ground

    In rheumatic heart disease-associated AF patients, VKAs therapy was non-inferior to rivaroxaban for a composite of cardiovascular events or death rates.

  • MIS-C in children after COVID-19: Origin in the gut?

    Multisystemic inflammatory syndrome can appear in children and adolescents as a consequence of SARS-CoV-2 infection.

  • The use of virtual reality in the physician-patient-relationship

    Surgery planning, education or even communication: Virtual and augmented reality give room to many applications in patient-physician interactions.

  • Allopurinol disappoints in ALL-HEART

    A prospective study showed that the medication did not reduce events, including non-fatal MI, non-fatal stroke, or cardiovascular death, in patients with IHD.

  • Positive results for subcutaneous pegozafermin in severe hypertriglyceridemia

    Treating severe hypertriglyceridaemia patients with subcutaneous pegozafermin significantly reduced triglycerides across all study dose groups.

  • Meta-analysis of DELIVER and EMPEROR-Preserved

    SGLT2 inhibitors reduced the risk of cardiovascular death and hospitalisation for heart failure across HFpEF/HFmrEF patient subgroups.

  • Medical therapy as good as PCI for ischaemic cardiomyopathy

    In severe ischaemic left ventricular systolic dysfunction patients, PCI did not reduce the composite incidence of all cause death or hospitalisation for heart failure.

  • "BOXing" out oxygen and blood pressure targets

    The BOX trial shows that outcomes of comatose patients after an OHCA are not affected by shifting targets of oxygenation or blood-pressure.

  • High-dose influenza vaccine: A mortality risk reduction?

    A high-dose vaccination (60 μg of haemagglutinin antigen) in older adults reduced death risk by 49% and hospitalisation by 64%, compared with standard-dose vaccination.

  • Therapy with proton pump inhibitors - when to continue, when to stop?

    PPIs should work against gastrointestinal complaints, but some patients need them permanently. Researchers have set therapy guidelines for this.

  • Acetazolamide + loop diuretics improves decongestion

    Adding acetazolamide to loop diuretics in ADHF patients with volume overload improved rates of successful decongestion within 3 days.

  • Danish study suggests starting CVD screening before age 70

    Results point to a screening target age below 70 years, for a substantial reduction of combined endpoints of death, stroke, or myocardial infarction.

  • 2 |
  • 3 |
  • 4 |
  • 5 |
  • 6 |
  • 7 |
  • 8 |
  • 9 |
  • 10 |
  • 11 |
  • 12 |